Drug Profile
Brepocitinib - Priovant Therapeutics
Alternative Names: Brepocitinib tosylate - Pfizer; PF 6700841; PF-06700841; PF-06700841-15; PF-841Latest Information Update: 08 Dec 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Pfizer; Priovant Therapeutics
- Class Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Arylsulfonic acids; Bridged-ring heterocyclic compounds; Cyclopropanes; Fluorinated hydrocarbons; Ketones; Pyrazoles; Pyrimidines; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dermatomyositis
- Phase II Crohn's disease; Hidradenitis suppurativa; Uveitis
- Discontinued Alopecia; Alopecia areata; Atopic dermatitis; Lupus vulgaris; Plaque psoriasis; Psoriatic arthritis; Systemic lupus erythematosus; Ulcerative colitis; Vitiligo
Most Recent Events
- 27 Nov 2023 Discontinued - Phase-II for Systemic lupus erythematosus (In the elderly, Treatment-experienced, In adults) in USA, Argentina, Australia, Bulgaria, Belgium, Canada, China, Colombia, Czech Republic, France, Germany, Greece, Hong Kong, Hungary, Italy, Italy, Japan, South Korea, South Korea, Japan, Mexico, Poland, Portugal, Romania, Serbia, Spain, Taiwan, Ukraine, United Kingdom (PO)
- 27 Nov 2023 Discontinued - Phase-II for Systemic lupus erythematosus (PO)
- 19 Oct 2023 Pfizer completes a phase-II trial in Crohn's disease (Treatment-experienced, Combination therapy) in USA, Australia, Austria, Bosnia-Herzegovina, Belgium, Canada, Croatia, Czech Republic, Georgia, Germany, Hungary, Italy, South Korea, Lebanon, Lithuania, Slovakia, South Africa, Saudi Arabia, Poland, Russia, Serbia, Spain, Switzerland, Tunisia, Turkey, Ukraine, United Arab Emirates (PO) (NCT03395184)